$966.64
al cierre: Nov 11 EDT
$969.20
2.560.26%
Pre-comercialización: 4:26 AM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Eli Lilly and Co tiene un precio objetivo de consenso de $966.79 basado en las calificaciones de 29 analistas. El máximo es $1190, emitido por Citigroup el enero 28, 2025. El mínimo es $700, emitido por HSBC el agosto 27, 2025. Las 3 calificaciones de analistas más recientes fueron publicadas por Freedom Capital Markets, Leerink Partners y UBS el noviembre 10, 2025, noviembre 10, 2025 y noviembre 7, 2025, respectivamente. Con un precio objetivo promedio de $1044.67 entre Freedom Capital Markets, Leerink Partners y UBS, hay una 7.79% upside implícita para Eli Lilly and Co según estas calificaciones más recientes de analistas.
Firmas de analistas que realizan recomendaciones1
Freedom Capital Markets
Leerink Partners
UBS
BMO Capital
Cantor Fitzgerald
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Eli Lilly
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/10/2025 | -1.98% | Freedom Capital Markets | $750 → $950 | Downgrade | Buy → Hold | |||
11/10/2025 | 13.91% | Leerink Partners | $886 → $1104 | Upgrade | Market Perform → Outperform | |||
11/07/2025 | 11.43% | UBS | $895 → $1080 | Maintains | Buy | |||
11/06/2025 | 13.5% | BMO Capital | $930 → $1100 | Maintains | Outperform | |||
10/31/2025 | 1.63% | Cantor Fitzgerald | $925 → $985 | Maintains | Overweight | |||
10/16/2025 | -2.19% | Guggenheim | $948 → $948 | Reiterates | Buy → Buy | |||
10/08/2025 | -2.19% | Guggenheim | $875 → $948 | Maintains | Buy | |||
10/03/2025 | 5.55% | Morgan Stanley | $1028 → $1023 | Maintains | Overweight | |||
09/17/2025 | -14.36% | Berenberg | $970 → $830 | Downgrade | Buy → Hold | |||
09/16/2025 | 8.34% | JP Morgan | $1100 → $1050 | Maintains | Overweight | |||
08/27/2025 | -27.78% | HSBC | $675 → $700 | Upgrade | Reduce → Hold | |||
08/13/2025 | -14.88% | Cantor Fitzgerald | $975 → $825 | Maintains | Overweight | |||
08/13/2025 | -9.72% | Guggenheim | $942 → $875 | Maintains | Buy | |||
08/11/2025 | -7.14% | Deutsche Bank | $1010 → $900 | Maintains | Buy | |||
08/08/2025 | 13.5% | JP Morgan | $1100 → $1100 | Reiterates | Overweight → Overweight | |||
08/08/2025 | -7.66% | UBS | $1050 → $895 | Maintains | Buy | |||
07/11/2025 | -2.81% | Guggenheim | $936 → $942 | Maintains | Buy | |||
07/10/2025 | 17.11% | Morgan Stanley | $1133 → $1135 | Maintains | Overweight | |||
06/20/2025 | -3.43% | Guggenheim | $936 → $936 | Reiterates | Buy → Buy | |||
05/02/2025 | 8.34% | UBS | $1100 → $1050 | Maintains | Buy | |||
04/28/2025 | -27.78% | HSBC | $1150 → $700 | Downgrade | Buy → Reduce | |||
04/22/2025 | 0.6% | Cantor Fitzgerald | → $975 | Initiates | → Overweight | |||
04/14/2025 | -4.25% | Guggenheim | $973 → $928 | Maintains | Buy | |||
04/09/2025 | 15.97% | Morgan Stanley | $1146 → $1124 | Maintains | Overweight | |||
04/08/2025 | -8.38% | Goldman Sachs | $892 → $888 | Upgrade | Neutral → Buy | |||
03/05/2025 | 13.5% | Wells Fargo | $970 → $1100 | Maintains | Overweight | |||
02/03/2025 | 7.1% | Truist Securities | $1029 → $1038 | Maintains | Buy | |||
01/28/2025 | 0.08% | Wells Fargo | $1000 → $970 | Maintains | Overweight | |||
01/28/2025 | 22.78% | Citigroup | $1250 → $1190 | Maintains | Buy | |||
12/10/2024 | 2.87% | B of A Securities | → $997 | Reinstates | → Buy | |||
11/15/2024 | 3.18% | Wolfe Research | → $1000 | Initiates | → Outperform | |||
11/04/2024 | 4.73% | Deutsche Bank | $1025 → $1015 | Maintains | Buy | |||
10/31/2024 | 6.17% | Truist Securities | $1033 → $1029 | Maintains | Buy | |||
10/31/2024 | 0.6% | Barclays | $1025 → $975 | Maintains | Overweight | |||
10/31/2024 | 13.5% | B of A Securities | $1150 → $1100 | Maintains | Buy | |||
10/25/2024 | 28.97% | Citigroup | $1060 → $1250 | Maintains | Buy | |||
10/17/2024 | 13.5% | Bernstein | — | → $1100 | Initiates | → Outperform | ||
10/10/2024 | 6.58% | Truist Securities | $1000 → $1033 | Maintains | Buy | |||
10/03/2024 | 5.76% | Deutsche Bank | $1025 → $1025 | Reiterates | Buy → Buy | |||
09/16/2024 | -8.69% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
09/13/2024 | 13.5% | JP Morgan | $1050 → $1100 | Maintains | Overweight | |||
09/13/2024 | 9.37% | Citigroup | → $1060 | Reinstates | Buy → Buy | |||
09/09/2024 | -8.69% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
08/27/2024 | 14.11% | Morgan Stanley | $1106 → $1106 | Reiterates | Overweight → Overweight | |||
08/19/2024 | -8.69% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
08/16/2024 | 6.27% | Guggenheim | $884 → $1030 | Maintains | Buy | |||
08/14/2024 | 8.34% | Berenberg | $1000 → $1050 | Maintains | Buy | |||
08/12/2024 | 5.76% | Deutsche Bank | $725 → $1025 | Upgrade | Hold → Buy | |||
08/09/2024 | 3.18% | Wells Fargo | $875 → $1000 | Maintains | Overweight | |||
08/09/2024 | 13.6% | BMO Capital | $1001 → $1101 | Maintains | Outperform | |||
08/09/2024 | 16.08% | B of A Securities | $1000 → $1125 | Maintains | Buy | |||
08/05/2024 | -8.79% | Guggenheim | $855 → $884 | Maintains | Buy | |||
08/05/2024 | -8.69% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
07/24/2024 | -8.69% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
07/15/2024 | -8.69% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
07/11/2024 | 3.18% | Berenberg | $850 → $1000 | Maintains | Buy | |||
07/11/2024 | 3.18% | JP Morgan | $900 → $1000 | Maintains | Overweight | |||
07/10/2024 | 5.76% | Barclays | $913 → $1025 | Maintains | Overweight | |||
07/05/2024 | 5.55% | Morgan Stanley | $1023 → $1023 | Maintains | Overweight | |||
07/03/2024 | 3.28% | BMO Capital | $1001 → $1001 | Maintains | Outperform | |||
07/01/2024 | -8.69% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/26/2024 | -8.69% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/25/2024 | -8.69% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/25/2024 | 3.18% | Truist Securities | $892 → $1000 | Reiterates | Buy → Buy | |||
06/24/2024 | 4.73% | Jefferies | $994 → $1015 | Maintains | Buy | |||
06/24/2024 | 3.18% | B of A Securities | $1000 → $1000 | Maintains | Buy | |||
06/24/2024 | -8.69% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/20/2024 | -8.69% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/17/2024 | -8.69% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/12/2024 | -8.69% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/11/2024 | -8.69% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/07/2024 | -1.26% | Jefferies | $925 → $957 | Maintains | Buy | |||
05/14/2024 | -13.33% | Argus Research | $770 → $840 | Maintains | Buy | |||
05/01/2024 | 3.28% | BMO Capital | $900 → $1001 | Maintains | Outperform | |||
05/01/2024 | -7.14% | JP Morgan | $850 → $900 | Maintains | Overweight | |||
05/01/2024 | -8.69% | Cantor Fitzgerald | $815 → $885 | Maintains | Overweight | |||
05/01/2024 | -7.97% | Truist Securities | $850 → $892 | Maintains | Buy | |||
04/30/2024 | -8.69% | Cantor Fitzgerald | $815 → $885 | Reiterates | Overweight → Overweight | |||
04/18/2024 | -15.91% | Cantor Fitzgerald | $815 → $815 | Reiterates | Overweight → Overweight | |||
04/15/2024 | -15.91% | Cantor Fitzgerald | $815 → $815 | Reiterates | Overweight → Overweight | |||
04/11/2024 | -25.4% | Goldman Sachs | $650 → $723 | Maintains | Neutral | |||
04/05/2024 | -15.91% | Cantor Fitzgerald | $815 → $815 | Reiterates | Overweight → Overweight | |||
04/03/2024 | — | Erste Group | — | Upgrade | Hold → Buy | |||
04/02/2024 | -7.66% | Citigroup | $675 → $895 | Maintains | Buy | |||
04/01/2024 | -15.91% | Cantor Fitzgerald | $815 → $815 | Reiterates | Overweight → Overweight | |||
03/22/2024 | -12.3% | Truist Securities | → $850 | Reiterates | Buy → Buy | |||
03/15/2024 | -12.3% | JP Morgan | $775 → $850 | Maintains | Overweight | |||
03/01/2024 | 3.18% | B of A Securities | $800 → $1000 | Maintains | Buy | |||
02/21/2024 | -15.39% | DZ Bank | → $820 | Downgrade | Buy → Hold | |||
02/20/2024 | -15.91% | Cantor Fitzgerald | $815 → $815 | Reiterates | Overweight → Overweight | |||
02/16/2024 | -1.98% | Morgan Stanley | $805 → $950 | Maintains | Overweight | |||
02/14/2024 | -15.91% | Cantor Fitzgerald | $815 → $815 | Reiterates | Overweight → Overweight | |||
02/07/2024 | -16.43% | Barclays | $680 → $810 | Maintains | Overweight | |||
02/07/2024 | -12.3% | Truist Securities | $650 → $850 | Maintains | Buy | |||
02/07/2024 | -16.94% | Morgan Stanley | $763 → $805 | Maintains | Overweight | |||
02/07/2024 | -14.88% | Wells Fargo | $700 → $825 | Maintains | Overweight | |||
02/07/2024 | -10.75% | BMO Capital | $710 → $865 | Maintains | Outperform | |||
02/06/2024 | -14.88% | Wells Fargo | $700 → $825 | Maintains | Overweight | |||
02/06/2024 | -15.91% | Cantor Fitzgerald | $630 → $815 | Maintains | Overweight | |||
02/05/2024 | -35% | Cantor Fitzgerald | → $630 | Reiterates | Overweight → Overweight |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Eli Lilly (LLY)?
El último precio objetivo de Eli Lilly (NYSE:LLY) fue comunicado por Freedom Capital Markets el noviembre 10, 2025. La firma de analistas fijó un precio objetivo para $950.00 que espera LLY a fall dentro de 12 meses (un posible -1.98% downside). 31 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Eli Lilly (LLY)?
La última calificación de analistas para Eli Lilly (NYSE:LLY) fue proporcionada por Freedom Capital Markets, y Eli Lilly rebajado su hold calificación.
¿Cuándo se produjo la última revisión al alza de Eli Lilly (LLY)?
La última revisión al alza de Eli Lilly and Co se produjo en noviembre 10, 2025, cuando Leerink Partners elevó su precio objetivo a $1104. Leerink Partners anteriormente tenía a market perform para Eli Lilly and Co.
¿Cuándo fue la última revisión a la baja de Eli Lilly (LLY)?
La última revisión a la baja de Eli Lilly and Co se produjo en noviembre 10, 2025, cuando Freedom Capital Markets cambió su precio objetivo de $750 a $950 para Eli Lilly and Co.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Eli Lilly (LLY)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Eli Lilly, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Eli Lilly se registró el noviembre 10, 2025, por lo que la próxima calificación estará disponible en torno al noviembre 10, 2026.
¿Es correcta la calificación de los analistas sobre Eli Lilly (LLY)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Eli Lilly (LLY) fue un rebajado con un precio objetivo de $750.00 a $950.00. El precio actual al que cotiza Eli Lilly (LLY) es de $969.20, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.